EU EMA Medicines Brief

Headline

EMA CHMP recommends EU marketing authorisation revocation for Tavneos following GCP breach finding in pivotal trial

Executive Summary

The EMA's Committee for Medicinal Products for Human Use recommended on June 27, 2026 that the EU marketing authorisation for Tavneos (avacopan) be revoked. The recommendation follows a data integrity review concluding that the pivotal Advocate study was conducted in breach of good clinical practice principles, rendering its efficacy data unreliable.

Bottom Line

The CHMP opinion removes the evidentiary foundation of the EU authorisation by declaring the Advocate study's data incorrect, misleading, and no longer capable of demonstrating efficacy. The benefit-risk balance fails on integrity grounds, not on new clinical harm data. Sponsors holding EU authorisations supported by a single pivotal study face a direct precedent: a post-approval GCP finding that invalidates study data is sufficient basis for revocation without a concurrent safety signal. The European Commission's binding decision is the next procedural gate.

Key Regulatory Signals

• Pivotal Trial Data Declared Unreliable: The CHMP found that data submitted from the 331-patient Advocate study were incorrect and misleading. The study can no longer support the authorisation, and post-marketing data and post-hoc analyses were insufficient to compensate for the evidentiary gap.
• GCP Breach as the Revocation Trigger: The revocation recommendation rests on a good clinical practice violation, not a new clinical safety signal. This framing means the authorisation fails on data integrity grounds rather than on an updated benefit-risk assessment based on new adverse-event evidence.
• Rare Disease Patient Population Loses Authorised Treatment Option: Tavneos is the only avacopan-based therapy authorised in the EU for adults with severe, active granulomatosis with polyangiitis or microscopic polyangiitis. Revocation removes an authorised treatment pathway for a rare-disease population with limited alternatives.
• Marketing Authorisation Holders Face Heightened Data Integrity Scrutiny: The CHMP's willingness to recommend revocation on data integrity grounds, independent of post-marketing safety signals, signals that sponsors holding EU authorisations based on a single pivotal study carry elevated exposure where that study's GCP compliance is subsequently questioned.
• European Commission Decision Pending: The CHMP opinion is a recommendation; the European Commission issues the binding decision. Until the Commission acts, the current marketing authorisation status remains in effect.

Regulatory Delta

- No direct EMA precedent exists for a revocation of a rare-disease authorisation driven by GCP breaches, where the sole pivotal study's data were found incorrect and misleading after approval.

- The revocation recommendation rests on data integrity failure rather than a post-market safety signal. This marks a structural departure from the typical benefit-risk reassessment pathway.

- The action has no immediate UK parallel; the MHRA holds a separate authorisation for Tavneos and has not issued a corresponding revocation recommendation as of this release.

Materiality Classification

HIGH — The CHMP recommendation triggers an immediate reassessment obligation for any EU-authorised product whose marketing authorisation rests on a single pivotal study, and establishes a first-in-kind precedent for GCP-breach-driven revocation in the rare-disease context without a concurrent safety signal.

Intelligence Outlook

Monitor the European Commission for the binding decision on this revocation recommendation and the EMA for any parallel referral or GCP inspection disclosure relating to the Advocate study sponsor.